TY - JOUR AU - Mandal, Pijush Kanti AU - Verma, Pushpendra AU - Prasad, Shivanna Poorna AU - Kumar, Prem AU - Gupta, Rahul PY - 2022/04/10 Y2 - 2024/03/29 TI - Telmisartan's effect on blood pressure in type 2 diabetes patients with and without complications JF - Medico Research Chronicles JA - Med. res. chronicles VL - 9 IS - 2 SE - Original Research Article DO - 10.26838/MEDRECH.2022.9.2.587 UR - https://medrech.com/index.php/medrech/article/view/570 SP - 107-115 AB - In people with type 2 diabetes, cardiovascular disease (CVD) is the leading cause of morbidity. Hypertension (HTN) frequently coexists with diabetes, increasing the risk of end-organ damage significantly. Blockers of the RAAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), have become a mainstay in the treatment of patients with diabetes plus hypertension. Telmisartan is the only ARB indicated for the treatment of atherothrombotic CVD (history of coronary heart disease, stroke, or peripheral arterial disease) or types 2 diabetes mellitus (T2DM) with confirmed target organ damage, therefore, reduction in the cardiovascular risk and morbidity. Trials of telmisartan have also been shown to reduce the progression of renal disease in individuals with diabetes and varying degrees of nephropathy, an effect that appears to be at least partly independent of a reduction in blood pressure. The present review article is intended to give comprehensive information about the effect of telmisartan on blood pressure in type 2 diabetes patients with and without complications. ER -